In the current study, we demonstrate the remarkable efficacy of two Spt5-Pol II inhibitors in a mouse model of HD and provide support for the potential of selective lowering of mutant Htt by small molecules as an effective therapeutic approach for the treatment of HD-associated neuropathology. Here, SUPT5H is linked to Huntington disease.